Loading company…
Morphic Medical develops an endoscopic device therapy for type 2 diabetes and obesity.
Morphic Medical, formerly GI Dynamics, develops the RESET® endoscopically delivered therapy for type 2 diabetes and obesity. The therapy is approved for sale in the European Union and is being studied in the United States. Based in Boston, US, the company raised USD 8 million from Crystal Amber in February 2026 to support clinical studies, regulatory work and distribution.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in